首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   85篇
  免费   1篇
  国内免费   1篇
儿科学   6篇
基础医学   21篇
口腔科学   4篇
临床医学   10篇
内科学   8篇
皮肤病学   5篇
神经病学   3篇
特种医学   5篇
外科学   4篇
综合类   8篇
预防医学   4篇
药学   5篇
中国医学   1篇
肿瘤学   3篇
  2020年   1篇
  2019年   1篇
  2016年   1篇
  2015年   2篇
  2014年   3篇
  2013年   2篇
  2012年   1篇
  2011年   3篇
  2010年   2篇
  2009年   3篇
  2008年   1篇
  2007年   7篇
  2006年   3篇
  2005年   1篇
  2004年   1篇
  2003年   1篇
  2002年   3篇
  2000年   1篇
  1998年   9篇
  1997年   6篇
  1996年   1篇
  1995年   5篇
  1994年   2篇
  1993年   3篇
  1988年   2篇
  1987年   2篇
  1986年   2篇
  1985年   4篇
  1984年   1篇
  1983年   2篇
  1980年   1篇
  1977年   2篇
  1976年   1篇
  1975年   1篇
  1974年   2篇
  1973年   1篇
  1972年   1篇
  1970年   2篇
排序方式: 共有87条查询结果,搜索用时 0 毫秒
11.
Hendrix  SL  Cochrane  BB  Nygaard  IE  沈平虎 《英国医学杂志》2006,9(1):48-49
问题:在绝经后健康妇女中,激素治疗(hormone therapy,HT)对尿失禁(urinary incontinence,UI)的效果如何?  相似文献   
12.
It would appear that it has become almost common practice to regard arachidonic acid (AA) as the sole precursor of eicosanoids. The fact that both dihomogamma-linolenic acid (DGLA) and eicosapentaenoic acid (EPA) give rise to distinct families of eicosanoids is commonly almost completely ignored. Elevated tissue levels of AA eicosanoids have been found in and have been implicated in the etiology of a number of diseases. Drugs which selectively block AA mobilization or its eicosanoid metabolism have therefore been developed for therapeutic use in these conditions. The fact that such drugs will also simultaneously block the eicosanoid metabolism from DGLA as well as from EPA is also commonly ignored. It is suggested that the profoundly adverse side-effects displayed by some of these drugs, resulting in some instances in their withdrawal from use, could be the direct result of their concomitant action of interfering with the eicosanoid metabolism of DGLA and EPA. It is further suggested that, before the interactions between the eicosanoids derived from AA and those derived from DGLA and EPA are understood, the use of drugs for the manipulation of AA eicosanoid metabolism in isolation, could be hazardous. This implies that all such drugs currently in use are to be regarded as experimental and provisionally toxic in terms of their effects on the whole system of eicosanoid metabolism. Thus even drugs which have been passed by the FDA and similar Drug Control Councils require total re-evaluation especially in view of the fact that the non-steroidal anti-inflammatory drugs are often prescribed for chronic conditions which require therapy for several years.(ABSTRACT TRUNCATED AT 250 WORDS)  相似文献   
13.
实验性高胆固醇血症兔离体主动脉功能变化的研究   总被引:2,自引:0,他引:2  
目的探讨高胆固醇血症对血管功能的影响。方法20只新西兰雄性兔随机分为2组正常饮食组(normal cholesterol,NC)10只及高胆固醇饮食组(hypercholesterol,HC)10只。4周后取出每只兔的降主动脉,5mm宽动脉环放置于含有25mlKreb液的组织-器官水浴系统中。分别测量游离血管对乙酰胆碱(10-10~10-5mol/L)的舒张反应及对去甲肾上腺素(10-10~10-5mol/L)的收缩反应。结果2组兔血胆固醇有显著差异,其中NC组(30.1±11.2)mg/dl,HC组(987.3±110.0)mg/dl(P<0.01);HC组血管对乙酰胆碱舒张反应与NC组比较明显减弱,HC组最大为(58.50±6.17)%,NC组最大为(103.2±6.9)%(P<0.01);HC组血管对去甲肾上腺素反应增强,最大收缩力HC组为(4.15±0.56)g,NC组为(2.9±0.3)g(P<0.05)。2组动脉病理学检查无动脉硬化的改变。结论高胆固醇血症降低血管内皮依赖性舒张反应,增加血管对去甲肾上腺素的收缩反应。高胆固醇血症时血管内皮功能改变早于动脉粥样硬化的结构改变。  相似文献   
14.
目的探讨2型糖尿病患者血浆同型半胱氨酸(homocysteine,Hcy)水平与冠心病是否相关。方法回顾性分析169例2型糖尿病并已行选择性冠脉造影的患者,按冠脉狭窄程度分为对照组,单支组,双支组和多支病变组,分析不同组别Hcy及其他临床生化指标。结果冠心病各亚组Hcy均高于对照组(P〈0.05),Hcy随冠脉病变程度的加重而升高,多支病变组Hcy明显高于单支组,与之呈正相关(P〈0.05);多元逐步回归分析显示血浆同型半胱氨酸与冠脉狭窄程度明显相关(P〈0.05)。结论2型糖尿病患者血浆同型半胱氨酸水平升高有可能加重冠脉粥样硬化。  相似文献   
15.
16.
Total obstruction of the airways caused all respiratory efforts to stop on 15 occasions in 10 preterm babies. This was not seen in 60 studies on 38 term babies. These findings suggest that failure to achieve an oral airway may not be the only mechanism by which upper airway obstruction might cause the cot death syndrome.  相似文献   
17.
It has been reported that oestradiol may play a role in the production of leptin from adipocytes. To investigate this relationship further, nine normally ovulating women were studied during two menstrual cycles, i.e. an untreated spontaneous cycle and a cycle treated with follicle stimulating hormone (FSH) from cycle day 2 until the day of human chorionic gonadotrophin (HCG) injection. Serum leptin values on cycle day 2 did not differ significantly between the spontaneous and the FSH cycles. In the spontaneous cycles, leptin values declined gradually and significantly up to day 7 and then increased progressively up to the day of luteinizing hormone (LH) surge onset, at which point they achieved the highest values. In the FSH cycles, serum leptin values increased gradually and significantly up to day 6, remaining stable thereafter, and were in the midfollicular phase significantly higher than in the spontaneous cycles. Significant positive correlations were found between mean values of leptin and mean values of oestradiol during the second half of the follicular phase in the spontaneous cycles and during the first half in the FSH cycles. A significant negative correlation was found between these two parameters in the spontaneous cycles during the first half of the follicular phase. Serum leptin levels were significantly higher in the midluteal than in the follicular phase in both cycles. These results demonstrate for the first time significant changes in leptin values during the follicular phase of the human menstrual cycle and a significant increase during superovulation induction with FSH. It is suggested that oestradiol may be involved in the regulation of leptin production in women.   相似文献   
18.
Great progress has been achieved during the last 20 years inthe field of ovulation induction in patients with polycysticovary syndrome (PCOS). Clomiphene citrate remains the firstline of treatment for all anovulatory women with PCOS, sincein properly selected patients the cumulative pregnancy rateapproaches that in normal women. Human urinary gonadotrophinshave been used extensively for ovulation induction but the developmentof low-dose regimens has opened a new era in the managementof anovulation related to PCOS. This article discusses the mainadvantages and disadvantages of the principal methods and regimenscurrently used for ovulation induction in patients with PCOSincluding clomiphene citrate, gonadotrophins, pulsatile gonadotrophin-releasinghormone (GnRH) and GnRH agonists. It also discusses new drugsdiscovered recently, particularly recombinant gonadotrophinsand GnRH antagonists, and provides some thoughts regarding theiruse in future protocols. Finally, based on the discovery ofnew ovarian substances which specifically control luteinizinghormone (LH) secretion, this article develops assumptions onpossible implications of these substances in the pathophysiologyof PCOS and their potential use in the management of the syndrome.  相似文献   
19.
20.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号